Clinical trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors…
NCT02054806 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02054806 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) |
| Official title | Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor |
| Intervention type | Biological |
| Interventions | Pembrolizumab |
| Enrollment | 477 |
| Start date | Feb 17, 2014 |
| Primary completion | Apr 30, 2021 |
| Completion | Apr 30, 2021 |
| First posted | Feb 4, 2014 |
| Last update posted | Oct 30, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: